Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages

Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages

Bibliographic Details
Main Authors:	Ping Ren, Yingxia Hu, Lei Peng, Luojia Yang, Kazushi Suzuki, Zhenhao Fang, Meizhu Bai, Liqun Zhou, Yanzhi Feng, Yongji Zou, Yong Xiong, Sidi Chen
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-07-01
Series:	Signal Transduction and Targeted Therapy
Online Access:	https://doi.org/10.1038/s41392-023-01509-1

Similar Items

Nanoparticle-based multivalent human antibodies offer potent and broad neutralization against Omicron sublineages
by: Yizhen Wang, et al.
Published: (2023-08-01)

Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
by: Xiaoman Li, et al.
Published: (2022-09-01)

Continued Complexity of Mutations in Omicron Sublineages
by: Austin N. Spratt, et al.
Published: (2022-10-01)

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
by: Yingdan Wang, et al.
Published: (2022-10-01)

First sequenced cases of Omicron BA.2 sublineage in Ecuador
by: D.A. Andrade-Molina, et al.
Published: (2023-09-01)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
by: Hongjie Xia, et al.
Published: (2023-12-01)

Rapid emergence of omicron sublineages expressing spike protein R346T
by: Ramona Groenheit, et al.
Published: (2023-01-01)

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
by: Qian Wang, et al.
Published: (2023-11-01)

Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity
by: Alexander Muik, et al.
Published: (2023-08-01)

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages
by: Li Guo, et al.
Published: (2023-12-01)

Diversity of Omicron sublineages and clinical characteristics in hospitalized patients in the southernmost state of Brazil
by: Jaqueline Rhoden, et al.
Published: (2024-02-01)

An mRNA vaccine with broad-spectrum neutralizing protection against Omicron variant sublineages BA.4/5 -included SARS-CoV-2
by: Ye Sang, et al.
Published: (2022-10-01)

Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages
by: Melanie R. Walker, et al.
Published: (2024-10-01)

Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2
by: Lia Fiaschi, et al.
Published: (2022-06-01)

Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase
by: Kevin E. Ramos, et al.
Published: (2024-07-01)

Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
by: Jianliang Xu, et al.
Published: (2024-07-01)

A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses
by: Yingdan Wang, et al.
Published: (2024-06-01)

Emergence of omicron variant's sublineages BA.4 and BA.5: risks assessment and possible countermeasures
by: Manish Dhawan, et al.
Published: (2022-07-01)

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
by: Shuai Xia, et al.
Published: (2022-07-01)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
by: Nutalai, R, et al.
Published: (2022)

Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity
by: Wagner, Koen, et al.
Published: (2018)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
by: Hong-fen Guo, et al.
Published: (2021-09-01)

Replication kinetics and infectivity of SARS-CoV-2 Omicron variant sublineages recovered in the Republic of Korea
by: Jeong-Min Kim, et al.
Published: (2024-06-01)

SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
by: Daniele Focosi, et al.
Published: (2023-10-01)

Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis
by: Lisa Askie, et al.
Published: (2023-07-01)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
by: Seth H. Pincus, et al.
Published: (2021-07-01)

Construction of Novel Bispecific Single-Domain Antibodies (BiSdAbs) with Potent Antiangiogenic Activities
by: Xianglei Liu, et al.
Published: (2020-03-01)

Reduced COVID-19 morbidity and mortality in hemodialysis patients across the various Omicron sublineages—A retrospective analysis
by: Max Schuller, et al.
Published: (2023-08-01)

Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD
by: Qianqian Li, et al.
Published: (2022-06-01)

Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence
by: Kathryn M. Hastie, et al.
Published: (2023-05-01)

Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V
by: Changchang Lu, et al.
Published: (2024-05-01)

Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes
by: Minghui Li, et al.
Published: (2024-12-01)

A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia
by: Sayed Shahabuddin Hoseini, et al.
Published: (2018-06-01)

1182 Bispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
by: Benjamin Doranz, et al.
Published: (2023-11-01)

Novel Human Metapneumovirus Sublineage
by: Barbara Huck, et al.
Published: (2006-01-01)

Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023
by: Jonathan Haars, et al.
Published: (2023-09-01)

Bispecific antibodies in follicular lymphoma
by: Imran A. Nizamuddin, et al.
Published: (2024-10-01)

Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017-04-01)

Bispecific antibodies in cancer immunotherapy
by: Eva Dahlén, et al.
Published: (2018-02-01)

Multi-omic characteristics of longitudinal immune profiling after breakthrough infections caused by Omicron BA.5 sublineagesResearch in context
by: Yanhua Li, et al.
Published: (2024-12-01)